{"date":"2025-08-02","count":1,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6589-2025-08-02-1240-1fo06ox","company_id":"6589","company":"台康生技","market":"上市","industry":"生技醫療","date":"2025-08-02","time":"12:40:24","subject":"本公司已透過歐盟臨床試驗資訊系統，向歐盟成員國波蘭及希臘提交研發中產品EG1206A(pertuzumab生物相似藥)第三期臨床試驗申請","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：台康生技（6589），2025-08-02 12:40，「本公司已透過歐盟臨床試驗資訊系統，向歐盟成員國波蘭及希臘提交研發中產品EG1206A(pertuzumab生物相似藥)第」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}